Bio-Rad Laboratories, Inc. (NYSE:BIO)‘s stock had its “buy” rating reiterated by stock analysts at Jefferies Group LLC in a report issued on Friday. They currently have a $275.00 target price on the medical research company’s stock. Jefferies Group LLC’s price objective would indicate a potential upside of 18.86% from the stock’s current price.

A number of other research firms also recently issued reports on BIO. Zacks Investment Research upgraded shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating and set a $244.00 target price for the company in a research report on Monday, May 1st. BidaskClub upgraded shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research report on Thursday, June 22nd. Wells Fargo & Company initiated coverage on shares of Bio-Rad Laboratories in a research report on Thursday. They set an “outperform” rating and a $250.00 target price for the company. Finally, Deutsche Bank AG upgraded shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating and decreased their target price for the company from $220.00 to $195.00 in a research report on Wednesday, June 28th. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $228.80.

Shares of Bio-Rad Laboratories (NYSE:BIO) traded down 0.12% during midday trading on Friday, reaching $231.37. 70,061 shares of the company’s stock were exchanged. Bio-Rad Laboratories has a one year low of $140.53 and a one year high of $232.07. The stock’s 50-day moving average is $222.92 and its 200 day moving average is $202.79. The firm has a market cap of $6.85 billion, a PE ratio of 245.62 and a beta of 0.91.

Bio-Rad Laboratories (NYSE:BIO) last posted its earnings results on Thursday, May 4th. The medical research company reported $0.41 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.27 by $0.14. The company had revenue of $500.05 million during the quarter, compared to the consensus estimate of $477.76 million. Bio-Rad Laboratories had a net margin of 1.35% and a return on equity of 3.23%. The firm’s quarterly revenue was up 6.1% on a year-over-year basis. During the same period in the previous year, the firm posted $0.42 earnings per share. Analysts anticipate that Bio-Rad Laboratories will post $2.94 EPS for the current year.

TRADEMARK VIOLATION WARNING: This piece was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/07/15/jefferies-group-llc-reaffirms-buy-rating-for-bio-rad-laboratories-inc-bio.html.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. FMR LLC purchased a new position in Bio-Rad Laboratories during the fourth quarter worth $30,186,000. Bank of New York Mellon Corp boosted its position in Bio-Rad Laboratories by 6.8% in the first quarter. Bank of New York Mellon Corp now owns 244,936 shares of the medical research company’s stock worth $48,826,000 after buying an additional 15,496 shares during the last quarter. Raymond James Financial Services Advisors Inc. purchased a new position in Bio-Rad Laboratories during the first quarter worth $1,253,000. Great West Life Assurance Co. Can boosted its position in Bio-Rad Laboratories by 3.9% in the first quarter. Great West Life Assurance Co. Can now owns 12,380 shares of the medical research company’s stock worth $2,467,000 after buying an additional 469 shares during the last quarter. Finally, Parametric Portfolio Associates LLC boosted its position in Bio-Rad Laboratories by 23.8% in the first quarter. Parametric Portfolio Associates LLC now owns 90,855 shares of the medical research company’s stock worth $18,111,000 after buying an additional 17,492 shares during the last quarter. 63.85% of the stock is owned by institutional investors.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.

Receive News & Ratings for Bio-Rad Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.